Abstract
A new method for the preparation of tetraketones 2-22 has been developed by using tetraethyl ammonium bromide (Et4N+Br¯) as a new reagent for condensation of dimedone (5,5-dimethyl cyclohexane-1,3- dione) and aldehydes. These compounds showed varying degrees of lipoxygenase inhibitory and antioxidant activities ranging between 7.8-198.0 and 33.6-248.0 μM, respectively. Compound 19 proved to be most active lipoxygenase inhibitor with IC50 value 7.8 μM in the present series. Out of twenty two tetraketones, four other compounds i.e. 3 (IC50 = 16.3 μM), 8 (IC50 = 21.3 μM), 11 (IC50 = 17.5 μM), 22 (IC50 = 12.5 μM) were also found to have excellent lipoxygenase inhibition, if compared to baicalein (IC50 = 22.4 μM) used as standard. On the other hand only compound 19 (IC50 = 33.6 μM) was found to be most antioxidant, if compared to standard t-butyl-4-hydroxyanisole (IC50 = 44.7 μM).
Keywords: Tetraketones, New Method, Lipoxygenase, Anti-oxidant, Asthma
Letters in Drug Design & Discovery
Title: An Alternative Method for the Synthesis of Tetraketones and their Lipoxygenase Inhibiting and Antioxidant Properties
Volume: 4 Issue: 4
Author(s): Khalid Mohammed Khan, Ghulam Murtaza Maharvi, Sarfraz Ahmed Nawaz, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Tetraketones, New Method, Lipoxygenase, Anti-oxidant, Asthma
Abstract: A new method for the preparation of tetraketones 2-22 has been developed by using tetraethyl ammonium bromide (Et4N+Br¯) as a new reagent for condensation of dimedone (5,5-dimethyl cyclohexane-1,3- dione) and aldehydes. These compounds showed varying degrees of lipoxygenase inhibitory and antioxidant activities ranging between 7.8-198.0 and 33.6-248.0 μM, respectively. Compound 19 proved to be most active lipoxygenase inhibitor with IC50 value 7.8 μM in the present series. Out of twenty two tetraketones, four other compounds i.e. 3 (IC50 = 16.3 μM), 8 (IC50 = 21.3 μM), 11 (IC50 = 17.5 μM), 22 (IC50 = 12.5 μM) were also found to have excellent lipoxygenase inhibition, if compared to baicalein (IC50 = 22.4 μM) used as standard. On the other hand only compound 19 (IC50 = 33.6 μM) was found to be most antioxidant, if compared to standard t-butyl-4-hydroxyanisole (IC50 = 44.7 μM).
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Murtaza Maharvi Ghulam, Ahmed Nawaz Sarfraz, Perveen Shahnaz and Iqbal Choudhary Muhammad, An Alternative Method for the Synthesis of Tetraketones and their Lipoxygenase Inhibiting and Antioxidant Properties, Letters in Drug Design & Discovery 2007; 4 (4) . https://dx.doi.org/10.2174/157018007784620004
DOI https://dx.doi.org/10.2174/157018007784620004 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews New Insights about Regulatory T Cells Distribution and Function with Exercise: The Role of Immunometabolism
Current Pharmaceutical Design Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Biomarkers in Asthma and COPD
Recent Patents on Biomarkers Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery Current Status and Future Prospects for Research on Tyrosine Sulfation
Current Pharmaceutical Biotechnology Pharmacological Interventions for the Prevention and Treatment of Kidney Injury Induced by Radiotherapy: Molecular Mechanisms and Clinical Perspectives
Current Molecular Pharmacology Transient Receptor Potential Vanilloid 1 Channel Modulation: A Novel Approach to Pain Therapy
Current Bioactive Compounds The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Multifunctional Lipoic Acid Conjugates
Current Medicinal Chemistry Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry How to Keep Oxidative Stress Under Control?
Current Nutrition & Food Science Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Vitamin D and Atopic Dermatitis
Mini-Reviews in Medicinal Chemistry